Principia taps Series A tranche to arm warheads for covalent drug IND
This article was originally published in Scrip
Principia Biopharma will use $12.5 million from the second tranche of a tiered Series A round totaling $36.3 million to file an investigational new drug (IND) application with the US FDA in 2013 for its first covalent drug.
You may also be interested in...
The French pharma adds the Phase I candidate to its Lemtrada follow-on for multiple sclerosis development, while Principia will use $40m in upfront cash to advance its orphan disease strategy.
Italfarmaco’s HDAC inhibitor helped ambulatory Duchenne muscular dystrophy patients climb stairs faster than non-treated boys while Capricor’s cell therapy improved upper limb function in non-ambulatory patients.
Private Company Edition: While the tough state of financing for publicly traded drug developers continues, venture capital firms and private biopharma companies revealed billions of dollars in new VC funds and start-up financings, including $100m-plus mega-rounds for Tessa, Alladapt and ImCheck.